CSL has priced US$1.5 billion of corporate bonds in the United States, turning to offshore debt markets to refinance its ...

An experimental treatment being developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit held for three months after treatment stopped, ...

Seven leading Chinese medical societies have jointly published an expert consensus naming Technegas the preferred ventilation agent for lung imaging in pulmonary embolism, handing the Sydney ...

Perth-based company PYC Therapeutics will take early human data on its polycystic kidney disease drug to the American Society of Nephrology conference in Denver on 22 October.

Australians living with wet age-related macular degeneration may soon be able to replace regular eye injections with a ...

Latest News; Young NZ cancer patients to get funded medicines no ma ...

Melbourne cryopreservation company Vitrafy Life Sciences has signed its third partnership with a US civilian blood network.

Hayley Tamborini, Arrotex's Chief Innovation Officer and Head of Government Affairs, called the listing an important step ...

Paradigm Biopharmaceuticals has entered voluntary administration. The Melbourne drug developer made the move after an interim ...

Hope for families and children at risk of Sanfilippo syndrome, often described as childhood dementia, with US regulatory ...

The guidance tells journalists that reporting on therapeutic goods is "unlikely" to be advertising where it adheres to ...